Cargando…

Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer

PURPOSE: Tryptophan metabolites have immunomodulatory functions, suggesting possible roles in cancer immunity. METHODS: Plasma tryptophan metabolites were measured using liquid chromatography/mass spectrometry before immune checkpoint inhibitors (ICIs) in patients with non-small cell lung cancer (NS...

Descripción completa

Detalles Bibliográficos
Autores principales: Karayama, M., Masuda, J., Mori, K., Yasui, H., Hozumi, H., Suzuki, Y., Furuhashi, K., Fujisawa, T., Enomoto, N., Nakamura, Y., Inui, N., Suda, T., Maekawa, M., Sugimura, H., Takada, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854397/
https://www.ncbi.nlm.nih.gov/pubmed/32533317
http://dx.doi.org/10.1007/s12094-020-02421-8
_version_ 1783646079628083200
author Karayama, M.
Masuda, J.
Mori, K.
Yasui, H.
Hozumi, H.
Suzuki, Y.
Furuhashi, K.
Fujisawa, T.
Enomoto, N.
Nakamura, Y.
Inui, N.
Suda, T.
Maekawa, M.
Sugimura, H.
Takada, A.
author_facet Karayama, M.
Masuda, J.
Mori, K.
Yasui, H.
Hozumi, H.
Suzuki, Y.
Furuhashi, K.
Fujisawa, T.
Enomoto, N.
Nakamura, Y.
Inui, N.
Suda, T.
Maekawa, M.
Sugimura, H.
Takada, A.
author_sort Karayama, M.
collection PubMed
description PURPOSE: Tryptophan metabolites have immunomodulatory functions, suggesting possible roles in cancer immunity. METHODS: Plasma tryptophan metabolites were measured using liquid chromatography/mass spectrometry before immune checkpoint inhibitors (ICIs) in patients with non-small cell lung cancer (NSCLC). RESULTS: The 19 patients with NSCLC had significantly lower levels of tryptophan (p = 0.002) and xanthurenic acid (p = 0.032), and a significantly higher level of 3-hydroxyanthranilic acid (3-HAA) (p = 0.028) compared with the 10 healthy volunteers. The patients achieving objective responses had significantly lower levels of 3-HAA than those who did not (p = 0.045). Receiver operating characteristic analyses determined that the cutoff value of 3-HAA for objective response was 35.4 pmol/mL (sensitivity: 87.5% and specificity: 83.3%). The patients with 3-HAA < 35.4 pmol/mL had significantly longer median progression-free survival (7.0 months) than those without (1.6 months, p = 0.022). CONCLUSIONS: Tryptophan metabolites may have a potential for predicting the efficacy of ICIs. REGISTRATION NUMBER: University Hospital Medical Information Network Clinical Trial Registry 000026140. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12094-020-02421-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7854397
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-78543972021-02-08 Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer Karayama, M. Masuda, J. Mori, K. Yasui, H. Hozumi, H. Suzuki, Y. Furuhashi, K. Fujisawa, T. Enomoto, N. Nakamura, Y. Inui, N. Suda, T. Maekawa, M. Sugimura, H. Takada, A. Clin Transl Oncol Brief Research Article PURPOSE: Tryptophan metabolites have immunomodulatory functions, suggesting possible roles in cancer immunity. METHODS: Plasma tryptophan metabolites were measured using liquid chromatography/mass spectrometry before immune checkpoint inhibitors (ICIs) in patients with non-small cell lung cancer (NSCLC). RESULTS: The 19 patients with NSCLC had significantly lower levels of tryptophan (p = 0.002) and xanthurenic acid (p = 0.032), and a significantly higher level of 3-hydroxyanthranilic acid (3-HAA) (p = 0.028) compared with the 10 healthy volunteers. The patients achieving objective responses had significantly lower levels of 3-HAA than those who did not (p = 0.045). Receiver operating characteristic analyses determined that the cutoff value of 3-HAA for objective response was 35.4 pmol/mL (sensitivity: 87.5% and specificity: 83.3%). The patients with 3-HAA < 35.4 pmol/mL had significantly longer median progression-free survival (7.0 months) than those without (1.6 months, p = 0.022). CONCLUSIONS: Tryptophan metabolites may have a potential for predicting the efficacy of ICIs. REGISTRATION NUMBER: University Hospital Medical Information Network Clinical Trial Registry 000026140. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12094-020-02421-8) contains supplementary material, which is available to authorized users. Springer International Publishing 2020-06-12 2021 /pmc/articles/PMC7854397/ /pubmed/32533317 http://dx.doi.org/10.1007/s12094-020-02421-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Brief Research Article
Karayama, M.
Masuda, J.
Mori, K.
Yasui, H.
Hozumi, H.
Suzuki, Y.
Furuhashi, K.
Fujisawa, T.
Enomoto, N.
Nakamura, Y.
Inui, N.
Suda, T.
Maekawa, M.
Sugimura, H.
Takada, A.
Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer
title Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer
title_full Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer
title_fullStr Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer
title_full_unstemmed Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer
title_short Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer
title_sort comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer
topic Brief Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854397/
https://www.ncbi.nlm.nih.gov/pubmed/32533317
http://dx.doi.org/10.1007/s12094-020-02421-8
work_keys_str_mv AT karayamam comprehensiveassessmentofmultipletryptophanmetabolitesaspotentialbiomarkersforimmunecheckpointinhibitorsinpatientswithnonsmallcelllungcancer
AT masudaj comprehensiveassessmentofmultipletryptophanmetabolitesaspotentialbiomarkersforimmunecheckpointinhibitorsinpatientswithnonsmallcelllungcancer
AT morik comprehensiveassessmentofmultipletryptophanmetabolitesaspotentialbiomarkersforimmunecheckpointinhibitorsinpatientswithnonsmallcelllungcancer
AT yasuih comprehensiveassessmentofmultipletryptophanmetabolitesaspotentialbiomarkersforimmunecheckpointinhibitorsinpatientswithnonsmallcelllungcancer
AT hozumih comprehensiveassessmentofmultipletryptophanmetabolitesaspotentialbiomarkersforimmunecheckpointinhibitorsinpatientswithnonsmallcelllungcancer
AT suzukiy comprehensiveassessmentofmultipletryptophanmetabolitesaspotentialbiomarkersforimmunecheckpointinhibitorsinpatientswithnonsmallcelllungcancer
AT furuhashik comprehensiveassessmentofmultipletryptophanmetabolitesaspotentialbiomarkersforimmunecheckpointinhibitorsinpatientswithnonsmallcelllungcancer
AT fujisawat comprehensiveassessmentofmultipletryptophanmetabolitesaspotentialbiomarkersforimmunecheckpointinhibitorsinpatientswithnonsmallcelllungcancer
AT enomoton comprehensiveassessmentofmultipletryptophanmetabolitesaspotentialbiomarkersforimmunecheckpointinhibitorsinpatientswithnonsmallcelllungcancer
AT nakamuray comprehensiveassessmentofmultipletryptophanmetabolitesaspotentialbiomarkersforimmunecheckpointinhibitorsinpatientswithnonsmallcelllungcancer
AT inuin comprehensiveassessmentofmultipletryptophanmetabolitesaspotentialbiomarkersforimmunecheckpointinhibitorsinpatientswithnonsmallcelllungcancer
AT sudat comprehensiveassessmentofmultipletryptophanmetabolitesaspotentialbiomarkersforimmunecheckpointinhibitorsinpatientswithnonsmallcelllungcancer
AT maekawam comprehensiveassessmentofmultipletryptophanmetabolitesaspotentialbiomarkersforimmunecheckpointinhibitorsinpatientswithnonsmallcelllungcancer
AT sugimurah comprehensiveassessmentofmultipletryptophanmetabolitesaspotentialbiomarkersforimmunecheckpointinhibitorsinpatientswithnonsmallcelllungcancer
AT takadaa comprehensiveassessmentofmultipletryptophanmetabolitesaspotentialbiomarkersforimmunecheckpointinhibitorsinpatientswithnonsmallcelllungcancer